|  |  |  |
| --- | --- | --- |
| Macintosh HD:Users:bilodeau:Desktop:logos:template 2017:un.emf | Macintosh HD:Users:bilodeau:Desktop:logos:template 2017:unep-old.emf | **CBD** |
| Macintosh HD:Users:bilodeau:Desktop:logos:template 2017:cbd.emf | | Distr.  GENERAL  CBD/CP/MOP/DEC/9/5  30 November 2018  ORIGINAL: ENGLISH |

CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY SERVING AS THE MEETING OF THE PARTIES TO THE CARTAGENA PROTOCOL ON BIOSAFETY

Ninth meeting

Sharm El-Sheikh, Egypt, 17-29 November 2018

Agenda item 10

Decision adopted by the Parties to the Cartagena Protocol on Biosafety

**9/5. Monitoring and reporting (Article 33)**

*The Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on Biosafety,*

*Recalling* decision [CP-VIII/14](http://bch.cbd.int/protocol/decisions/?decisionID=13542), in which the Executive Secretary was requested to develop a revised format for the fourth national reports with a view to ensuring that complete and accurate information is captured while striving to ensure the applicability of the baseline information, established in decision [BS‑VI/15](http://bch.cbd.int/protocol/decisions/?decisionID=13248),

*Welcoming* the review by the Subsidiary Body on Implementation at its second meeting of the draft revised format for the fourth national report, as proposed by the Executive Secretary,[[1]](#footnote-1)

*Recognizing* the importance of improving the alignment of national reporting under the Convention and its Protocols and of enhancing synergies among the biodiversity-related conventions and the Rio conventions as well as the 2030 Agenda for Sustainable Development[[2]](#footnote-2) and reporting tools for the Sustainable Development Goals, and *noting* the progress made thus far in this respect,

1. *Welcomes* the additional third national reports submitted, and *urges* the Parties that have not yet submitted their third national report to do so as soon as possible;[[3]](#footnote-3)
2. *Adopts* the reporting format annexed hereto, and *requests* Parties to use it for the fourth national report on the implementation of the Cartagena Protocol on Biosafety;
3. *Invites* Parties to prepare their reports through a consultative process involving all relevant national stakeholders, including indigenous peoples and local communities, as appropriate;
4. *Encourages* Parties to respond to all questions in the reporting format, and stresses the importance of the timely submission of fourth national reports in order to facilitate the fourth assessment and review of the effectiveness of the Cartagena Protocol and the final evaluation of the Strategic Plan for the Cartagena Protocol on Biosafety for the period 2011-2020;[[4]](#footnote-4)
5. *Requests* Parties and invites other Governments to submit to the Secretariat their fourth national report on the implementation of the Cartagena Protocol on Biosafety:

(a) In an official language of the United Nations;

(b) Twelve months prior to the tenth meeting of the Conference of the Parties serving as the meeting of the Parties to the Protocol, which will consider the report;

(c) Preferably online through the Biosafety Clearing-House, or offline using the appropriate form that will be made available by the Secretariat for this purpose, duly signed by the national focal point for the Cartagena Protocol;

1. *Requests* the Executive Secretary to continue making available, in the online reporting tool, the option to view and select the answers provided in the previous national report submitted by the Party concerned;
2. *Also requests* the Executive Secretary to continue to facilitate the offline submission of national reports;
3. *Recommends* to the Conference of the Parties, in adopting guidance to the financial mechanism, that it invite the Global Environment Facility to make available, in a timely manner, financial resources to eligible Parties to facilitate the preparation and submission of their fourth national reports under the Protocol;
4. *Accepts* the invitation of the Conference of the Parties to the Convention, contained in decision 14/27, and *decides* to have a synchronized national reporting cycle commencing in 2023.

*Annex*

**Updated draft format for the fourth national report under the Cartagena Protocol on Biosafety**

**Origin of the report**

|  |  |
| --- | --- |
| 1. **Country:** | **[ Type your text here ]** |
| *Contact person submitting the report* |  |
| 1. Name: | **[ Type your text here ]** |
| 1. Title: | **[ Type your text here ]** |
| 1. Organization: | **[ Type your text here ]** |
| 1. Mailing address: | **[ Type your text here ]** |
| 1. Telephone: | **[ Type your text here ]** |
| 1. Fax: | **[ Type your text here ]** |
| 1. E-mail: | **[ Type your text here ]** |
| 1. Organizations/stakeholders who were consulted or participated in the preparation of this report: | **[ Type your text here ]** |
| *Submission* |  |
| 1. Date of submission: | **[ day / month / year ]** |
| 1. Time period covered by this report: | **From [month / year] to [month / year]** |

Signature of the reporting officer[[5]](#footnote-5) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |
| --- | --- |
| 1. If your country is not a Party to the Cartagena Protocol on Biosafety (CPB), is there any national process in place towards becoming a Party? | Yes  No |
| 1. Here you may provide further details:   [ Type your text here ] | |
| **Article 2 – General provisions**  *Article 2 requires each Party to take the necessary and appropriate legal, administrative and other measures to implement its obligations under the Protocol* | |
| 1. Has your country introduced the necessary national measures for the implementation of the Protocol? | National measures are fully in place  National measures are partially in place  Only temporary measures have been introduced  Only draft measures exist  No measures have yet been taken |
| 1. Which specific instruments are in place for the implementation of national biosafety measures? | One or more national biosafety laws  One or more national biosafety regulations  One or more sets of biosafety guidelines  Other laws, regulations or guidelines that indirectly apply to biosafety  No instruments are in place |
| 1. Has your country undertaken initiatives to mainstream biosafety into national biodiversity strategies and action plans, other policies, or legislation? | Yes: [Please specify]  No  Other: [Please specify] |
| 1. Has your country established a mechanism for budget allocations for the operation of its national biosafety measures? | Yes  Yes, to some extent: [Please specify]  No |
| 1. Does your country have permanent staff to administer functions directly related to biosafety? | Yes  No |
| 1. If you answered *Yes* to question 18, how many permanent staff members are in place whose functions are directly related to biosafety ? | 1 to 4  5 to 9  10 or more  *Is this number adequate:  Yes  No* |
| 1. Here you may provide further details on the implementation of Article 2 in your country:   [ Type your text here ] | |
| **Article 5 – Pharmaceuticals** | |
| 1. Does your country regulate the transboundary movement, handling or use of living modified organisms (LMOs) which are pharmaceuticals to humans? | Yes  Yes, to some extent: [Please specify]  No |
| 1. Here you may provide further details on the implementation of Article 5 in your country:   [ Type your text here ] | |
| **Article 6 – Transit and contained use** | |
| 1. Does your country regulate the transit of LMOs? | Yes  Yes, to some extent: [Please specify]  No |
| 1. Does your country regulate the contained use of LMOs? | Yes  No |
| 1. Has your country taken a decision concerning the import of LMOs for contained use? | Yes  No |
| 1. Here you may provide further details on the implementation of Article 6 in your country:   [ Type your text here ] | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Articles 7 to 10: Advance informed agreement (AIA) and  intentional introduction of LMOs into the environment** | | | |
| 1. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure? | | | Yes  Yes, to some extent: [Please specify]  No |
| 1. When acting as the Party of export, has your country established legal requirements for the accuracy of information contained in the notification provided by the exporter? | | | Yes  Yes, to some extent: [Please specify]  No  Not applicable (Party currently not exporting LMOs) |
| 1. In the current reporting period, has your country received a notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment? | | | Yes  No |
| 1. If you answered *Yes* to question 29, did the notification(s) contain complete information (at a minimum the information specified in Annex I to the Cartagena Protocol on Biosafety)? | | | Yes, always  In some cases only  No |
| 1. If you answered *Yes* to question 29, has your country acknowledged receipt of the notification(s) to the notifier within ninety days of receipt? | | | Yes, always  In some cases only  No |
| 1. If you answered *Yes* to question 29, has your country informed of its decision(s): | | | |
| a. The notifier? | Yes, always  In some cases only  No | | |
| b. The Biosafety Clearing-House (BCH)? | Yes, always  In some cases only  No | | |
| 1. In the current reporting period, has your country taken a decision in response to the notification(s) regarding intentional transboundary movements of LMOs for intentional introduction into the environment? | | | Yes  No |
| 1. If you answered *Yes* to question 33, how many LMOs has your country approved for import for intentional introduction into the environment? | | | None  1 to 4  5 to 9  10 or more |
| 1. If you answered *under question 34* that *LMOs were approved*, have all these LMOs actually been imported into your country? | | | Yes, always  In some cases only  No |
| 1. If you answered *Yes* to question 33, what percentage of your country’s decisions fall into the following categories? | | | [ %] Approval of the import/use of the LMO(s) without conditions  [ %] Approval of the import/use of the LMO(s) with conditions  [ %] Prohibition of the import/use of the LMO(s)  [ %] Request for additional relevant information  [ %] Inform the notifier that the period for communicating the decision has been extended |
| 1. If you answered *under question 36* that your country has taken a decision to *approve the import with conditions* or to *prohibit the import*, were the reasons provided? | | | Yes, always  In some cases only  No |
| 1. Here you may provide further details on the implementation of Articles 7 to 10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:   [ Type your text here ] | | | |
| **Article 11 – Procedure for living modified organisms  intended for direct use as food or feed, or for processing (LMOs-FFP)** | | | |
| 1. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | Yes  No | | |
| 1. Has your country established legal requirements for the accuracy of information to be provided by the applicant regarding the domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | Yes  Yes, to some extent: [Please specify]  No | | |
| 1. In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | None  1 to 4  5 to 9  10 or more | | |
| 1. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding the import of LMOs for direct use as food or feed, or for processing? | Yes  No | | |
| 1. In the current reporting period, how many decisions has your country taken regarding the import of LMOs for direct use as food or feed, or for processing? | None  1 to 4  5 to 9  10 or more | | |
| 1. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing:   [ Type your text here ] | | | |
| **Article 12 – Review of decision** | | | |
| 1. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs? | Yes  Yes, to some extent: [Please specify]  No | | |
| 1. In the current reporting period, has your country reviewed and/or changed a decision regarding an intentional transboundary movement of an LMO? | Yes  No | | |
| 1. If you answered *Yes* to question 46, how many decisions were reviewed and/or changed? | 1 to 4  5 to 9  10 or more | | |
| 1. If you answered *Yes* to question 46, were any of the reviews triggered by a request from the Party of export or the notifier? | Yes  No | | |
| 1. If you answered *Yes* to question 48, did your country provide a response within ninety days setting out the reasons for the decision? | Yes, always  In some cases only  No | | |
| 1. If you answered *Yes* to question 46, were any of the reviews initiated by your country as the Party of import? | Yes  No | | |
| 1. If you answered *Yes* to question 50, did your country, within thirty days, set out the reasons for the decision and inform: | | | |
| a. The notifier? | Yes, always  In some cases only  No | | |
| b. The BCH? | Yes, always  In some cases only  No | | |
| 1. Here you may provide further details on the implementation of Article 12 in your country:   [ Type your text here ] | | | |
| **Article 13 – Simplified procedure** | | | |
| 1. Has your country established a mechanism for the application of the simplified procedure regarding an intentional transboundary movement of LMOs? | Yes  Yes, to some extent: [Please specify]  No | | |
| 1. In the current reporting period, has your country applied the simplified procedure? | Yes  No | | |
| 1. If you answered *Yes* to question 54, for how many LMOs has your country applied the simplified procedure? | None  1 to 5  5 or more | | |
| 1. If you answered *Yes* to question 54, has your country informed the Parties through the BCH of the cases where the simplified procedure was applied? | Yes, always  In some cases only  No | | |
| 1. Here you may provide further details on the implementation of Article 13 in your country:   [ Type your text here ] | | | |
| **Article 14 – Bilateral, regional and multilateral agreements and arrangements** | | | |
| 1. How many bilateral, regional or multilateral agreements or arrangements relevant to biosafety has your country established with other Parties/non-Parties? | None  1 to 4  5 to 9  10 or more | | |
| 1. If you answered *under question 58* that *agreements or arrangements were established*, please provide a brief description of their scope and objective:   [ Type your text here ] | | | |
| 1. Here you may provide further details on the implementation of Article 14 in your country:   [ Type your text here ] | | | |
| **Articles 15 & 16 – Risk assessment and risk management** | | | |
| 1. Does the domestic regulatory framework of your country require risk assessments of LMOs to be conducted? | Yes  No | | |
| 1. If you answered *Yes* to question 61, with regard to which LMOs does the requirement apply (select all that apply)? | For imports of LMOs for intentional introduction into the environment  For imports of LMOs intended for direct use as food or feed, or for processing  For decisions regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movements for direct use as food or feed, or for processing  For imports of LMOs for contained use  Other: [Please specify] | | |
| 1. Has your country established a mechanism to conduct risk assessments prior to taking decisions regarding LMOs? | Yes  Yes, to some extent: [Please specify]  No | | |
| 1. If you answered *Yes* to question 63, does the mechanism include procedures to identify and/or train national experts to conduct risk assessments? | Yes  No | | |
| *Capacity-building in risk assessment or risk management* | | | |
| 1. How many people in your country have been trained in risk assessment, risk management and monitoring of LMOs? | | | |
| a. Risk assessment: | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| b. Risk management: | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| c. Monitoring: | | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| 1. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs? | | Yes  No | |
| 1. If you answered *Yes* to question 66, is your country using the “Manual on Risk Assessment of LMOs” (developed by the CBD Secretariat) for training in risk assessment? | | Yes  No | |
| 1. If you answered *Yes* to question 66, is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment? | | Yes  No | |
| 1. Does your country have specific needs for further guidance on specific topics of risk assessment of LMOs? | | Yes: [Please specify]  No | |
| 1. Does your country have the capacity to detect, identify, assess the risk of and/or monitor LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health? | | | |
| a. Detect: | | Yes  No | |
| b. Identify: | | Yes  No | |
| c. Assess the risk: | | Yes  No | |
| d. Monitor: | | Yes  No | |
| *Conducting risk assessment or risk management* | | | |
| 1. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers? | | | |
| a. Risk assessment: | | Yes  No | |
| b. Risk management: | | Yes  No | |
| 1. If you answered *Yes* to question 71, is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers? | | Yes  No | |
| 1. Has your country adopted common approaches or methodologies to risk assessment in coordination with other countries? | | Yes  No | |
| 1. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity? | | Yes  No | |
| 1. In the current reporting period, has your country conducted any kind of risk assessment of LMOs, including for contained use, field trials, commercial purposes, direct use as food, feed, or for processing? | | Yes  No | |
| 1. If you answered *Yes* to question 75, how many risk assessments were conducted? | | 1 to 9  10 to 49  50 to 99  More than 100 | |
| 1. If you answered *Yes* to question 75, please indicate the scope of the risk assessments (select all that apply): | | LMOs for contained use (in accordance with Article 3)  LMOs for intentional introduction into the environment for experimental testing or field trials  LMOs for intentional introduction into the environment for commercial purposes  LMOs for direct use as food  LMOs for direct use as feed  LMOs for processing  Other: [Please specify] | |
| 1. If you answered *Yes* to question 75, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing? | | Yes, always  In some cases only  No | |
| 1. Has your country established appropriate mechanisms, measures and strategies to regulate and manage risks identified in the risk assessment of LMOs? | | Yes  No | |
| 1. Has your country taken appropriate measures to prevent unintentional transboundary movements of LMOs, including such measures as requiring a risk assessment to be carried out prior to the first release of a LMO? | | Yes  No | |
| 1. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use? | | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Has your country established a mechanism for monitoring potential effects of LMOs released into the environment? | | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Does your country have the necessary infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs? | | Yes  No | |
| 1. Here you may provide further details on the implementation of Articles 15 and 16 in your country:   [ Type your text here ] | | | |
| **Article 17 – Unintentional transboundary movements**[[6]](#footnote-6) **and emergency measures** | | | |
| 1. Has your country established measures to notify affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations in case of a release under its jurisdiction that leads, or may lead, to an unintentional transboundary movement? | | Yes  Yes, to some extent: [Please specify]  No | |
| 1. In the current reporting period, how many releases of LMOs occurred under your country’s jurisdiction that led, or may have led, to an unintentional transboundary movement? | | None  1 to 4  5 to 9  10 or more | |
| 1. If you answered *under question 86* that a *release occurred*, has your country notified affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations? | | Yes, always  In some cases only  No | |
| 1. Does your country have the capacity to take appropriate response measures in response to unintentional transboundary movements? | | Yes  No | |
| 1. In the current reporting period, how many times has your country become aware of an unintentional transboundary movement into its territory? | | None  1 to 4  5 to 9  10 or more | |
| 1. Here you may provide further details on the implementation of Article 17 in your country:   [ Type your text here ] | | | |

|  |  |  |
| --- | --- | --- |
| **Article 18 – Handling, transport, packaging and identification** | | |
| 1. Has your country taken measures to require that *LMOs that are subject to transboundary movement* are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Has your country taken measures to require that documentation accompanying LMOs-FFP, *in cases* *where the identity of the LMOs is not known,* clearly identifies that they *may contain LMOs* and are not intended for intentional introduction into the environment, as well as a contact point for further information? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Has your country taken measures to require that documentation accompanying LMOs-FFP, *in cases where the identity of the LMOs is known*, clearly identifies that they *contain LMOs* and are not intended for intentional introduction into the environment, as well as a contact point for further information? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. If you answered *Yes* to question(s) 91, 92 and/or 93, what type of documentation accompanying LMOs does your country require? | Documentation specific for LMOs  As part of other documentation (not specific for LMOs)  Other: [Please specify] | |
| 1. Has your country taken measures to require that documentation accompanying *LMOs that are destined for contained use* clearly identifies them as *LMOs* and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. If you answered *Yes* to question 95, what type of documentation does your country require for the identification of LMOs that are destined for contained use? | Documentation specific for LMOs  As part of other documentation (not specific for LMOs)  Other: [Please specify] | |
| 1. Has your country taken measures to require that documentation accompanying *LMOs that are intended for intentional introduction into the environment of the Party of import*, clearly identifies them as *living modified organisms*; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. If you answered *Yes* to question 97, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment? | Documentation specific for LMOs  As part of other documentation (not specific for LMOs)  Other: [Please specify] | |
| 1. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms? | Yes  No | |
| 1. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. How many customs officers in your country have received training in the identification of LMOs? | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| 1. Has your country established procedures for the sampling and detection of LMOs? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. How many laboratory personnel in your country have received training in detection of LMOs? | None  1 to 9  10 to 49  50 to 99  100 or more  *Is this number adequate:  Yes  No* | |
| 1. Does your country have reliable access to laboratory facilities for the detection of LMOs? | Yes  No | |
| 1. How many laboratories in your country are certified for LMO detection? | None  1 to 4  5 to 9  10 to 49  50 or more | |
| 1. If you answered *under question 105* that *certified laboratories exist in your country*, how many of them are currently operating in the detection of LMOs? | None  1 to 4  5 to 9  10 to 49  50 or more | |
| 1. Here you may provide further details on the implementation of Article 18 in your country:   [ Type your text here ] | | |
| **Article 19 – Competent national authorities and national focal points** | | |
| 1. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs? | Yes  No  Not applicable (no competent national authority was designated)  Not applicable (only one competent national authority was designated) | |
| 1. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Has your country undertaken initiatives to strengthen collaboration among national focal points, competent national authority(ies) and other institutions on biosafety-related matters? | Yes: [Please specify]  No | |
| 1. Here you may provide further details on the implementation of Article 19 in your country:   [ Type your text here ] | | |
| **Article 20 – Information sharing and the Biosafety Clearing-House (BCH)** | | |
| 1. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. | | |
| 1. Existing legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a)) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Legislation, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Bilateral, multilateral and regional agreements and arrangements (Article 14, paragraph 2, and Article 20, paragraph 3 (b)) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e)) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions by a Party regarding transit of LMOs (Article 6, paragraph 1) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions by a Party regarding import of LMOs for contained use (Article 6, paragraph 2) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Notifications regarding the release under your country’s jurisdiction that leads, or may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects on biological diversity (Article 17, paragraph 1) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Information concerning cases of illegal transboundary movements of LMOs (Article 25, paragraph 3) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions regarding the importation of LMOs for intentional introduction into the environment (Article 10, paragraph 3) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with Annex III to the Protocol (Article 11, paragraph 6) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1 (a)) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. LMOs granted exemption status by each Party (Article 13, paragraph 1 (b)) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c)) | Information available and in the BCH  Information available but not in the BCH  Information available but only partially available in the BCH  Information not available | |
| 1. Please provide a brief explanation if you answered that the information is available *but not in the BCH* or *only partially available in the BCH* to any item under question 112:   [ Type your text here ] | | |
| 1. Has your country established a mechanism for strengthening the capacity of the BCH national focal point to perform its administrative functions? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Has your country established a mechanism for the coordination among the BCH national focal point, the Cartagena Protocol national focal point, and the competent national authority(ies) for making information available to the BCH? | Yes  Yes, to some extent: [Please specify]  No | |
| 1. Does your country use the information available in the BCH in its decision-making processes on LMOs? | Yes, always  Yes, in some cases  No  Not applicable (no decisions were taken) | |
| 1. Has your country experienced difficulties accessing or using the BCH? | Yes: [Please specify]  No | |
| 1. In the current reporting period, how many biosafety-related events (e.g. seminars, workshops, press conferences, educational events) has your country organized? | None  1 to 4  5 to 9  10 to 24  25 or more | |
| 1. In the current reporting period, how many biosafety-related publications has your country published? | None  1 to 9  10 to 49  50 to 99  100 or more | |
| 1. Here you may provide further details on the implementation of Article 20 in your country:   [ Type your text here ] | | |
| **Article 21 – Confidential information** | | |
| 1. Has your country established procedures to protect confidential information received under the Protocol? | | Yes  Yes, to some extent: [Please specify]  No |
| 1. Does your country allow the notifier to identify information that is to be treated as confidential? | | Yes, always  In some cases only  No |
| 1. Here you may provide further details on the implementation of Article 21 in your country:   [ Type your text here ] | | |
| **Article 22 – Capacity-building** | | |
| 1. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol? | | Yes  Yes, to some extent: [Please specify]  No |
| 1. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety? | | Yes  Yes, to some extent: [Please specify]  No |
| 1. If you answered *Yes* to question 125, how were these resources made available? | | Bilateral channels  Regional channels  Multilateral channels |
| 1. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety? | | Yes  Yes, to some extent: [Please specify]  No |
| 1. If you answered *Yes* to question 127, how were these resources made available? | | Bilateral channels  Regional channels  Multilateral channels |
| 1. In the reporting period, has your country initiated a process to access funds from the Global Environment Facility (GEF) for building capacity in biosafety? | | Yes: [Please specify]  No |
| 1. If you answered *Yes* to question 129, how would you characterize the process? | | Very easy  Easy  Average  Difficult  Very difficult |
| 1. In the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety? | | Yes  Yes, to some extent: [Please specify]  No |
| 1. If you answered *Yes* to question 131, in which of the following areas were these activities undertaken (select all that apply)? | | Institutional capacity and human resources  Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)  Risk assessment and other scientific and technical expertise  Risk management  Public awareness, participation and education in biosafety  Information exchange and data management, including participation in the Biosafety Clearing-House  Scientific, technical and institutional collaboration at subregional, regional and international levels  Technology transfer  Identification of LMOs, including their detection  Socioeconomic considerations  Implementation of the documentation requirements under Article 18.2 of the Protocol  Handling of confidential information  Measures to address unintentional and/or illegal transboundary movements of LMOs  Scientific biosafety research relating to LMOs  Taking into account risks to human health  Liability and redress  Other: [Please specify] |
| 1. In the current reporting period, has your country carried out a capacity-building needs assessment? | | Yes  No |
| 1. Does your country still have capacity-building needs? | | Yes  No |
| 1. If you answered *Yes* to question 134, which of the following areas still need capacity-building (select all that apply)? | | Institutional capacity and human resources  Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)  Risk assessment and other scientific and technical expertise  Risk management  Public awareness, participation and education in biosafety  Information exchange and data management, including participation in the Biosafety Clearing-House  Scientific, technical and institutional collaboration at subregional, regional and international levels  Technology transfer  Sampling, detection and identification of LMOs  Socioeconomic considerations  Implementation of the documentation requirements for handling, transport, packaging and identification  Handling of confidential information  Measures to address unintentional and/or illegal transboundary movements of LMOs  Scientific biosafety research relating to LMOs  Taking into account risks to human health  Liability and redress  Other: [Please specify] |
| 1. Has your country developed a capacity-building strategy or action plan? | | Yes  No |
| 1. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives? | | Yes  No |
| 1. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:   [ Type your text here ] | | |

|  |  |
| --- | --- |
| **Article 23 – Public awareness and participation** | |
| 1. Is biosafety public awareness, education and/or participation addressed in legislation or policy in your country? | Yes  Yes, to some extent: [Please specify]  No |
| 1. In the current reporting period, has your country cooperated with other States and international bodies in relation to public awareness, education and participation? | Yes: [Please specify]  No |
| 1. Has your country established a mechanism to ensure public access to information on LMOs? | Yes  Yes, to some extent: [Please specify]  No |
| 1. Does your country have in place a national communication strategy on biosafety? | Yes: [Please specify]  No |
| 1. Does your country have any awareness and outreach programmes on biosafety? | Yes: [Please specify]  No |
| 1. Does your country currently have a national biosafety website? | Yes  No |
| 1. How many academic institutions in your country are offering biosafety education and training courses and programmes? | None  1 to 4  5 to 9  10 or more  *Is this number adequate:  Yes  No* |
| 1. How many educational materials and/or online modules on biosafety are available and accessible to the public in your country? | None  1 to 4  5 to 9  10 to 24  25 to 99  100 or more  *Is this number adequate:  Yes  No* |
| 1. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs? | Yes  Yes, to some extent: [Please specify]  No |
| 1. Has your country informed the public about existing modalities for public participation in the decision-making process regarding LMOs? | Yes  Yes, to some extent: [Please specify]  No |
| 1. If you answered *Yes* to question 148, please indicate the modalities used to inform the public: | National websites  Newspapers  Forums  Mailing lists  Public hearings  Social media  Other: [Please specify] |
| 1. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs? | None (decisions taken without consultation)  1 to 4  5 or more  Not applicable (no decisions were taken) |
| 1. Has your country informed the public about the means to access the Biosafety Clearing-House? | Yes  No |
| 1. Here you may provide further details on the implementation of Article 23 in your country:   [ Type your text here ] | |
| **Article 24 – Non-Parties** | |
| 1. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs? | Yes  No |
| 1. In the current reporting period, has your country imported LMOs from a non-Party? | Yes  No |
| 1. In the current reporting period, has your country exported LMOs to a non-Party? | Yes  No |
| 1. If you answered *Yes* to question 154 and/or 155, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety? | Yes, always  In some cases only  No |
| 1. Here you may provide further details on the implementation of Article 24 in your country:   [ Type your text here ] | |
| **Article 25 – Illegal transboundary movements**[[7]](#footnote-7) | |
| 1. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement the Cartagena Protocol? | Yes  Yes, to some extent: [Please specify]  No |
| 1. In the current reporting period, how many cases of illegal transboundary movements of LMOs has your country become aware of? | None  1 to 4  5 to 9  10 or more |
| 1. If you indicated *under question 159* that *your country became aware of cases of illegal transboundary movements*, has the origin of the LMO(s) been established? | Yes  Yes, some cases  No |
| 1. Here you may provide further details on the implementation of Article 25 in your country:   [ Type your text here ] | |
| **Article 26 – Socio-economic considerations** | |
| 1. Does your country have any specific approaches or requirements that facilitate how socioeconomic considerations should be taken into account in LMO decision-making? | Yes  No |
| 1. In the current reporting period, have socioeconomic considerations arising from the impact of LMOs been taken into account in decision-making? | Yes, always  In some cases only  No  Not applicable (no decisions were taken) |
| 1. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socioeconomic considerations? | None  1 to 4  5 to 9  10 to 49  50 or more  *Is this number adequate:  Yes  No* |
| 1. Has your country cooperated with other Parties on research and information exchange on any socioeconomic impacts of LMOs? | Yes  No |
| 1. Here you may provide further details on the implementation of Article 26 in your country:   [ Type your text here ] | |
| |  | | --- | | **Article 28 – Financial mechanism and resources** | | |
| 1. In the current reporting period, how much funding (in the equivalent of US dollars) has your country mobilized to support implementation of the Cartagena Protocol beyond the regular national budgetary allocation? | Nothing  1 to 4,999 USD  5,000 to 49,999 USD  50,000 to 99,999 USD  100,000 to 499,000 USD  500,000 USD or more |
| **Article 33 – Monitoring and reporting**  *Article 33 requires Parties to monitor the implementation of its obligations under the Cartagena Protocol and to report to the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on measures taken to implement the Protocol* | |
| 1. Does your country have in place a system to monitor and enforce the implementation of the Cartagena Protocol? | Yes  No |
| **Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress**  *Parties to the Cartagena Protocol that are not yet Party to the Supplementary Protocol are also invited to respond to the questions below* | |
| 1. Is your country a Party to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress? | Yes  No |
| 1. If you answered *No* to question 169, is there any national process in place towards becoming a Party to the Supplementary Protocol? | Yes  No |
| 1. Has your country introduced the necessary measures for the implementation of the Supplementary Protocol? | National measures are fully in place  National measures are partially in place  Only temporary measures have been introduced  Only draft measures exist  No measures have yet been taken |
| 1. Which instruments are in place for the implementation of the Supplementary Protocol? | One or more national laws: [Please specify]  One or more national regulations: [Please specify]  One or more sets of guidelines: [Please specify]  No instruments are in place |
| 1. Does your country have administrative or legal instruments that require response measures to be taken: |  |
| a. In case of damage resulting from LMOs? | Yes  No |
| b. In case there is sufficient likelihood that damage will result if response measures are not taken? | Yes  No |
| 1. If you answered *Yes* to question 173a, do these instruments impose requirements on an operator (select all that apply)? | Yes, the operator must inform the competent authority of the damage  Yes, the operator must evaluate the damage  Yes, the operator must take response measures  Yes, other requirements: [Please specify]  No |
| 1. If you answered *Yes* to question 173a, do these instruments require the operator to take response measures to avoid damage? | Yes  No |
| 1. If you answered *Yes* to question 173a or 173b, do these instruments provide for a definition of “operator”? | Yes  No |
| 1. If you answered *Yes* to question 176, which of the following could be an ‘operator’ (select all that apply)? | Permit holder  Person who placed the LMO on the market  Developer  Producer  Notifier  Exporter  Importer  Carrier  Supplier  Other: [Please specify] |
| 1. Has a competent authority been identified for carrying out the functions set out in the Supplementary Protocol? | Yes: [Please specify]  No |
| 1. If you answered *Yes* to question 178, what measures may the competent authority take (select all that apply)? | Identify the operator that caused the damage  Evaluate the damage  Determine response measures to be taken by operator  Implement response measures  Recover costs and expenses of the evaluation of the damage and the implementation of any response measures from the operator  Other: [Please specify] |
| 1. Does your country have measures in place to provide for financial security for damage resulting from LMOs? | Yes  No |
| 1. If you answered *Yes* to question 180, what type of financial security measures are in place (select all that apply)? | Requirement to provide evidence for secure source of funding  Mandatory insurance  Government schemes, including funds  Other: [Please specify] |
| 1. Does your country have rules and procedures on civil liability that address damage resulting from LMOs, or has such damage been recognized in court rulings (select all that apply)? | Yes, in a civil liability instrument  Yes, in court rulings  Yes, in other instruments: [Please specify]  No |
| 1. Have there been any occurrences of damage resulting from LMOs in your country? | Yes: [Please specify]  No |
| 1. If you answered *Yes* to question 183, have response measures been taken? | Yes: [Please specify]  No |
| 1. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:   [ Type your text here ] | |
| **Other information** | |
| 1. Please use this field to provide any other information on issues related to national implementation of the Cartagena Protocol and the Supplementary Protocol, including any obstacles or impediments encountered.   [ Type your text here ] | |
| **Comments on reporting format** | |
| 1. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.   [ Type your text here ] | |

\_\_\_\_\_\_\_\_\_\_

1. See [CBD/SBI/2/22](https://www.cbd.int/doc/c/05b3/3c25/2cc04a53ad3360ce1a1b940e/sbi-02-22-en.pdf), sect. I, recommendation 2/13. [↑](#footnote-ref-1)
2. General Assembly resolution 70/1 of 25 September 2015. [↑](#footnote-ref-2)
3. Angola, Azerbaijan, Belize, Cabo Verde, Djibouti, Jordan, Libya, Montenegro, Nauru, Papua New Guinea, Qatar, Saudi Arabia, Serbia, Seychelles, State of Palestine and Syrian Arab Republic. [↑](#footnote-ref-3)
4. Decision [BS-V/16](https://bch.cbd.int/protocol/decisions/decision.shtml?decisionID=12329), annex I. [↑](#footnote-ref-4)
5. This document is a protected form in MS Word format to enable further processing of the information contained therein by the CBD Secretariat. Only text entries and checkboxes may be changed. Once you finish filling in the form, please save it and print this first page for signature. This form is also available in the BCH for electronic submission at: [LINK TO BE ADDED]

   **IMPORTANT: To facilitate the analysis of the information contained in this report, it is recommended that Parties submit the report online through the Biosafety Clearing-House or as an attachment to an e-mail in MS Word format, together with a scanned copy of the signed first page, to the Secretariat at:** [**secretariat@cbd.int**](mailto:secretariat@cbd.int)**.**

   **Please *do not* send this report via fax or postal mail or in electronic formats other than MS Word.** [↑](#footnote-ref-5)
6. In accordance with the operational definition adopted in decision CP-VIII/16, “‘Unintentional transboundary movement’ is a transboundary movement of a living modified organism that has inadvertently crossed the national borders of a Party where the living modified organism was released, and the requirements of Article 17 of the Protocol apply to such transboundary movements only if the living modified organism involved is likely to have significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, in the affected or potentially affected States.” [↑](#footnote-ref-6)
7. In accordance with the operational definition adopted in decision CP VIII/16, “‘Illegal transboundary movement’ is a transboundary movement of living modified organisms carried out in contravention of the domestic measures to implement the Protocol that have been adopted by the Party concerned”. [↑](#footnote-ref-7)